Abiopharma

News list

Theravance Biopharma US Inc (TBPH)

Event
Aug. 04, 2022, 20:18 UTC

(19% Negative) THERAVANCE BIOPHARMA, INC. (TBPH) Reports Q3 2022 Financial Results

Full text

News bot Oct. 2, 2025, 6:57 p.m.

📋 THERAVANCE BIOPHARMA, INC. (TBPH) - Financial Results

Filing Date: 2022-08-04

Accepted: 2022-08-04 16:18:56

Event Type: Financial Results

Event Details:

Theravance Biopharma US Inc (TBPH) Reports Q3 2022 Financial Results Theravance Biopharma US Inc (TBPH) announced its financial results for the period ending Q3 2022. Key Financial Highlights:

Revenue: 11050
Net Income: Not disclosed
EPS: Not disclosed
Cash and equivalents: 132850

📊 Key Financial Metrics (Year-over-Year Comparison):

Metric	2022	2021	Change ($)	Change (%)
Current Assets Cash Equivalents Marketable Securities	132.85K	173.47K	$-40.62K	-23.41%
Current Assets Property Equipment Net	12.53K	13.66K	$-1.13K	-8.24%
Current Assets Other Assets	3.30K	3.23K	$75.00	+2.32%
Liabilities And Shareholders Deficit Other Long Term Liabilities	2.61K	2.73K	$-122.00	-4.47%
Costs And Expenses Selling General Administrative	25.93K	34.83K	$-8.90K	-25.55%
Costs And Expenses Loss From Operations	64.11K	65.38K	$-1.27K	-1.94%
Costs And Expenses Interest Expense	11.61K	23.54K	$-11.93K	-50.67%
Costs And Expenses Net Loss	52.41K	34.14K	$18.27K	+53.51%
Selling, General & Administrative	7.63K	11.29K	$-3.67K	-32.47%
Property and Equipment, Net	13.66K	13.66K	$0.00	+0.00%
Other Assets	3.23K	3.23K	$0.00	+0.00%
Operating Lease Liabilities	52.68K	52.68K	$0.00	+0.00%
Revenue	1.98K	181.00	$1.80K	+993.92%
Loss from Operations	64.11K	65.38K	$-1.27K	-1.94%
Interest Expense	11.61K	23.54K	$-11.93K	-50.67%
Interest Income	1.17K	2.06K	$-894.00	-43.29%
Net Loss	52.41K	34.14K	$18.27K	+53.51%

💼 Business Developments:

Partnership
Acquisition: Not available
Licensing
Regulatory Approval
Executive Changes: Not available

Structured Data:

Company Name: Theravance Biopharma US Inc
CIK: 0001583107
Ticker Symbol: TBPH
Period End Date: 2022-08-04
Document Type: 8-K